We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
+5.66%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$80.1B
AUM Growth
+$9.71B
(+14%)
Cap. Flow
+$17.3B
Cap. Flow
% of AUM
21.56%
Top 10 Holdings %
Top 10 Hldgs %
29.43%
Holding
1,430
New
62
Increased
858
Reduced
440
Closed
53
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$13B |
| 2 |
NVIDIA
NVDA
|
+$468M |
| 3 |
ASML
ASML
|
+$424M |
| 4 |
Applied Materials
AMAT
|
+$310M |
| 5 |
Qualcomm
QCOM
|
+$307M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kinross Gold
KGC
|
+$444M |
| 2 |
Tyler Technologies
TYL
|
+$256M |
| 3 |
C.H. Robinson
CHRW
|
+$251M |
| 4 |
Philip Morris
PM
|
+$245M |
| 5 |
RTX Corp
RTX
|
+$234M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 40.76% |
| 2 | Materials | 26.89% |
| 3 | Healthcare | 7.04% |
| 4 | Industrials | 6.5% |
| 5 | Financials | 5.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1251
Alphatec Holdings
ATEC
$1.59B
| $99K | ﹤0.01% |
19,273
+6,998
| +57% | +$53.7K |
|
1252
Symbotic
SYM
$6.04B
| $99K | ﹤0.01% |
3,497
+774
| +28% | +$21K |
|
1253
Lindsay Corp
LNN
$1.2B
| $97K | ﹤0.01% |
852
-351
| -29% | -$42.1K |
|
1254
Ituran Location and Control
ITRN
$1.12B
| $94K | ﹤0.01% |
3,479
-206
| -6% | -$5.49K |
|
1255
Vital Farms
VITL
$521M
| $94K | ﹤0.01% |
2,622
-1,473
| -36% | -$52.1K |
|
1256
NGL Energy Partners
NGL
$1.98B
| $93K | ﹤0.01% |
22,246
-2,319
| -9% | -$10.4K |
|
1257
United Natural Foods
UNFI
$2.94B
| $90K | ﹤0.01% |
4,357
-2,227
| -34% | -$31.9K |
|
1258
Globant
GLOB
$1.65B
| $86K | ﹤0.01% |
398
+153
| +62% | +$29.6K |
|
1259
Hims & Hers Health
HIMS
$7.44B
| $82K | ﹤0.01% |
3,836
-1,648
| -30% | -$29.5K |
|
1260
Doximity
DOCS
$3.99B
| $81K | ﹤0.01% |
1,964
-626
| -24% | -$20.9K |
|
1261
Ultragenyx Pharmaceutical
RARE
$2.54B
| $81K | ﹤0.01% |
1,487
-457
| -24% | -$23.3K |
|
1262
Corebridge Financial
CRBG
$14.1B
| $79K | ﹤0.01% |
2,520
+143
| +6% | +$4.04K |
|
1263
Fomento Económico Mexicano
FMX
$43B
| $78K | ﹤0.01% |
802
+306
| +62% | +$33K |
|
1264
LeMaitre Vascular
LMAT
$2.42B
| $75K | ﹤0.01% |
861
-51
| -6% | -$4.42K |
|
1265
ReNew
RNW
$2.29B
| $72K | ﹤0.01% |
12,278
+4,513
| +58% | +$26.8K |
|
1266
CRISPR Therapeutics
CRSP
$5.23B
| $71K | ﹤0.01% |
1,546
-78,228
| -98% | -$3.97M |
|
|
BPMC
1267
DELISTED
Blueprint Medicines
BPMC
| $64K | ﹤0.01% |
753
-363
| -33% | -$36.1K |
|
1268
Dr. Reddy's Laboratories
RDY
$10.1B
| $64K | ﹤0.01% |
4,115
+1,610
| +64% | +$25.9K |
|
|
STKL
1269
DELISTED
SunOpta
STKL
| $63K | ﹤0.01% |
10,973
-3,390
| -24% | -$19.9K |
|
1270
Hain Celestial
HAIN
$48.7M
| $61K | ﹤0.01% |
7,251
-1,472
| -17% | -$11K |
|
|
EQC
1271
DELISTED
Equity Commonwealth
EQC
| $61K | ﹤0.01% |
3,103
+632
| +26% | +$12.6K |
|
1272
Ouster
OUST
$3.22B
| $57K | ﹤0.01% |
7,264
+1,608
| +28% | +$15.3K |
|
1273
Yum China
YUMC
$16.4B
| $57K | ﹤0.01% |
1,290
-220
| -15% | -$7.32K |
|
1274
Kanzhun
BZ
$7.35B
| $52K | ﹤0.01% |
+3,510
| New | +$51.1K |
|
1275
New Jersey Resources
NJR
$5.79B
| $52K | ﹤0.01% |
+1,111
| New | +$50.7K |
|
Similar funds
VanEck Associates's Q3 2024 Portfolio in Review
As of Q3 2024, VanEck Associates held 1,430 positions worth $80.1B, up 14% from $70.4B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
VanEck Associates deployed $17.3B of net new capital in Q3 2024, opening 62 new positions and adding to 858 existing holdings. Its largest new stake was GE HealthCare: 2,335,235 shares worth $209M.
By sector, the portfolio is most concentrated in Technology at 41% of assets, down from 42% a quarter earlier, followed by Materials and Healthcare.
On the sell side, the largest reduction was Kinross Gold, an estimated $444M trimmed.
- VanEck Associates's largest Q3 2024 buy was GE HealthCare: 2,335,235 shares worth $209M.
- VanEck Associates added most to Lam Research in Q3 2024, an estimated $13B increase.
- VanEck Associates's biggest Q3 2024 reduction was Kinross Gold, cutting an estimated $444M.
- VanEck Associates fully exited RBC Bearings Incorporated 5.00% Series A Mandatory Convertible Preferred Stock in Q3 2024, selling an estimated $22.4M.
- VanEck Associates's ten largest holdings make up 29% of its $80.1B portfolio in Q3 2024.
- VanEck Associates opened 62 new positions and closed 53 in Q3 2024.
- VanEck Associates's portfolio value rose 14% quarter-over-quarter to $80.1B.
Based on VanEck Associates's 13F filing for Q3 2024, filed 29 Oct 2024.